Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
Yoshiya TanakaSang-Cheol BaeDamon L BassPaula CurtisMyron ChuKathleen DeRoseBeulah N JiRegina KurraschJenny LowePaige MeizlikDavid A RothPublished in: RMD open (2021)
Favourable safety profile and treatment responses were maintained for ≤7 years in patients with SLE from Japan and South Korea.